These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 35798882)

  • 21. Oncolytic viruses as a promising therapeutic strategy for hematological malignancies.
    Yang C; Hua N; Xie S; Wu Y; Zhu L; Wang S; Tong X
    Biomed Pharmacother; 2021 Jul; 139():111573. PubMed ID: 33894623
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Caspase-3-dependent cleavage of Bcl-xL in the stroma exosomes is required for their uptake by hematological malignant cells.
    Vardaki I; Sanchez C; Fonseca P; Olsson M; Chioureas D; Rassidakis G; Ullén A; Zhivotovsky B; Björkholm M; Panaretakis T
    Blood; 2016 Dec; 128(23):2655-2665. PubMed ID: 27742710
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies.
    Deckert J; Wetzel MC; Bartle LM; Skaletskaya A; Goldmacher VS; Vallée F; Zhou-Liu Q; Ferrari P; Pouzieux S; Lahoute C; Dumontet C; Plesa A; Chiron M; Lejeune P; Chittenden T; Park PU; Blanc V
    Clin Cancer Res; 2014 Sep; 20(17):4574-83. PubMed ID: 24987056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Role of Extracellular Vesicles in the Pathogenesis of Hematological Malignancies: Interaction with Tumor Microenvironment; a Potential Biomarker and Targeted Therapy.
    Das K; Mukherjee T; Shankar P
    Biomolecules; 2023 May; 13(6):. PubMed ID: 37371477
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic role of controlling nutritional status score in hematological malignancies.
    Zhang Y; Chen Q; Lu C; Yu L
    Hematology; 2022 Dec; 27(1):653-658. PubMed ID: 35622088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of extracellular vesicles in normal hematopoiesis and hematological malignancies.
    Ghafouri-Fard S; Niazi V; Taheri M
    Heliyon; 2021 Jan; 7(1):e06030. PubMed ID: 33521365
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Hematopoietic malignancy (leukemia, malignant lymphoma, multiple myeloma)].
    Nosaka K; Kawaguchi T
    Nihon Rinsho; 2012 May; 70(5):835-9. PubMed ID: 22620009
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Role of Exosomes in the Progression and Therapeutic Resistance of Hematological Malignancies.
    Wang H; You Y; Zhu X
    Front Oncol; 2022; 12():887518. PubMed ID: 35692747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Extracellular vesicles and their role in hematological malignancies].
    Rzepiel A; Kutszegi N; Cs Sági J; Kelemen A; Pálóczi K; F Semsei Á; Buzás E; Erdélyi DJ
    Orv Hetil; 2016 Aug; 157(35):1379-84. PubMed ID: 27569460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Role of RNA-Binding Proteins in Hematological Malignancies.
    Aguilar-Garrido P; Otero-Sobrino Á; Navarro-Aguadero MÁ; Velasco-Estévez M; Gallardo M
    Int J Mol Sci; 2022 Aug; 23(17):. PubMed ID: 36076951
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Programmed death-1 immune checkpoint blockade in the treatment of hematological malignancies.
    Tsirigotis P; Savani BN; Nagler A
    Ann Med; 2016 Sep; 48(6):428-439. PubMed ID: 27224873
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Research Advances on the Biological Characteristics of Hematological Malignant Cells Immunologically Regulated by Exosome--Review].
    Jiang XY; Yang YZ; Hu XL; Chen HJ; Li J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Feb; 28(1):339-342. PubMed ID: 32027300
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current knowledge on therapeutic, diagnostic, and prognostics applications of exosomes in multiple myeloma: Opportunities and challenges.
    Ramezani A; Tafazoli A; Salimi F; Ghavami M; Arjmandi H; Khalesi B; Hashemi ZS; Khalili S
    Arch Biochem Biophys; 2024 Jun; 756():109994. PubMed ID: 38626818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chemokine receptor CXCR4: An important player affecting the molecular-targeted drugs commonly used in hematological malignancies.
    Li L; Chai Y; Wu C; Zhao L
    Expert Rev Hematol; 2020 Dec; 13(12):1387-1396. PubMed ID: 33170753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MiR-26a-5p as a Reference to Normalize MicroRNA qRT-PCR Levels in Plasma Exosomes of Pediatric Hematological Malignancies.
    Damanti CC; Gaffo E; Lovisa F; Garbin A; Di Battista P; Gallingani I; Tosato A; Pillon M; Carraro E; Mascarin M; Elia C; Biffi A; Bortoluzzi S; Mussolin L
    Cells; 2021 Jan; 10(1):. PubMed ID: 33429910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel therapeutic approach for hematological malignancies based on cellular differentiation and apoptosis.
    Kizaki M; Nakazato T; Ito K; Kawamura C; Miyakawa Y; Ikeda Y
    Int J Hematol; 2002 Aug; 76 Suppl 1():250-2. PubMed ID: 12430859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Do exosomes play role in cardiovascular disease development in hematological malignancy?
    Zadeh FJ; Ghasemi Y; Bagheri S; Maleknia M; Davari N; Rezaeeyan H
    Mol Biol Rep; 2020 Jul; 47(7):5487-5493. PubMed ID: 32319009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New targets for CAR T therapy in hematologic malignancies.
    Savani M; Oluwole O; Dholaria B
    Best Pract Res Clin Haematol; 2021 Sep; 34(3):101277. PubMed ID: 34625226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Nanomedicines for the treatment of hematological malignancies.
    Deshantri AK; Varela Moreira A; Ecker V; Mandhane SN; Schiffelers RM; Buchner M; Fens MHAM
    J Control Release; 2018 Oct; 287():194-215. PubMed ID: 30165140
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted therapy for hematologic malignancies.
    Kuriakose P
    Cancer Control; 2005 Apr; 12(2):82-90. PubMed ID: 15855891
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.